Basilea Pharmaceutica (XSWX:BSLN) Institutional Ownership: 28.69% (As of Jul. 19, 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

XSWX:BSLN Basilea Pharmaceutica Ltd XSWX:BSLN
58 GF Score
Price CHF51.80
GF Value CHF57.78
Valuation Modestly Undervalued
! 2 Warning Signs
View Full Analysis

What is Basilea Pharmaceutica Institutional Ownership?

Basilea Pharmaceutica XSWX:BSLN 58 Institutional Ownership is 28.69% as of Jul. 19, 2026. GuruFocus rates XSWX:BSLN with a GF Score™ of 58/100 and a GF Value™ of CHF57.78 (Modestly Undervalued). The stock has 2 warning signs investors should review.

Institutional ownership is the percentage of shares that are owned by institutions out of the total shares outstanding. As of today, Basilea Pharmaceutica's institutional ownership is 28.69%.

Insider Ownership is the percentage of shares that are owned by company insiders relative to the total shares outstanding. As of today, Basilea Pharmaceutica's Insider Ownership is 0.00%.

Float Percentage Of Total Shares Outstanding is the percentage of float shares relative to the total shares outstanding. As of today, Basilea Pharmaceutica's Float Percentage Of Total Shares Outstanding is 0.00%.

Basilea Pharmaceutica Institutional Ownership Historical Data

* Premium members only.

The historical data trend for Basilea Pharmaceutica's Institutional Ownership can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Basilea Pharmaceutica Institutional Ownership Chart

Basilea Pharmaceutica Historical Data

The historical data trend for Basilea Pharmaceutica can be seen below:

2025-09-30 2025-10-31 2025-11-30 2025-12-31 2026-01-31 2026-02-28 2026-03-31 2026-04-30 2026-05-31 2026-06-30
Institutional Ownership 25.76 25.82 26.29 26.55 27.06 28.19 28.34 28.92 29.13 28.69
XSWX:BSLN
58GF Score
Basilea Pharmaceutica Ltd XSWX:BSLN
Institutional Ownership is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Basilea Pharmaceutica Institutional Ownership Calculation

The percentage of shares that are owned by institutions out of the total shares outstanding.

What does a Institutional Ownership of 28.69% mean?
Basilea Pharmaceutica (XSWX:BSLN) has a Institutional Ownership of 28.69% as of Jul. 19, 2026. Institutional ownership equals the percent of shares owned by financial institutions relative to total shares. View historical data on Basilea Pharmaceutica and its competitors.
Is Basilea Pharmaceutica's Institutional Ownership too high?
Basilea Pharmaceutica's current Institutional Ownership is 28.69%. Overall, Basilea Pharmaceutica has a GF Score™ of 58/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Basilea Pharmaceutica's Institutional Ownership compare to VRTX and REGN?
Basilea Pharmaceutica's Institutional Ownership of 28.69% can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Institutional Ownership for a Biotechnology company?
A good Institutional Ownership depends on the Biotechnology industry context. However, Institutional Ownership should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Institutional Ownership mean?
A high Institutional Ownership can signal that a stock is expensive relative to its fundamentals. Institutional ownership equals the percent of shares owned by financial institutions relative to total shares. View historical data on Basilea Pharmaceutica and its competitors. Basilea Pharmaceutica's current Institutional Ownership is 28.69%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Basilea Pharmaceutica stock overvalued right now?
Based on GuruFocus' analysis, Basilea Pharmaceutica (XSWX:BSLN) is currently considered Modestly Undervalued. The stock's GF Value™ is CHF57.78, compared to a current price of CHF51.80 — trading 10.3% below its estimated fair value. The current Institutional Ownership is 28.69%. Basilea Pharmaceutica's overall GF Score™ is 58/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Institutional Ownership calculated?
Institutional Ownership is calculated from a company's financial statements. For Basilea Pharmaceutica (XSWX:BSLN), the current Institutional Ownership is 28.69% as of Jul. 19, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Basilea Pharmaceutica (XSWX:BSLN) Overvalued in 2026?

Based on GuruFocus' analysis, Basilea Pharmaceutica stock appears to be undervalued. The current stock price of CHF51.80 is trading 10.3% below its estimated GF Value™ of CHF57.78. GuruFocus considers Basilea Pharmaceutica to be Modestly Undervalued.

Key valuation signals for XSWX:BSLN:

  • Institutional Ownership: 28.69%
  • GF Value™: CHF57.78 vs. price of CHF51.80 (10.3% below fair value)
  • GF Score™: 58/100 with 2 warning signs

No single metric tells the full story. See the XSWX:BSLN stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Basilea Pharmaceutica Business Description

Address Hegenheimermattweg 167b, Allschwil, CHE, 4123
Basilea Pharmaceutica Ltd is a commercial-stage biopharmaceutical company committed to discovering, developing and commercializing drugs to meet the needs of patients with severe bacterial and fungal infections. The Company has operating subsidiaries in the United Kingdom and Germany. Geographically company derives revenue from Japan, Ireland, Republic of Korea, USA, Uruguay, Sweden, Canada, Jordan, Switzerland and Other countries.
58GF Score

Get the complete analysis for XSWX:BSLN

Institutional Ownership is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

CHF51.80
Price
CHF57.78
GF Value